Gefitinib as First-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients in Southern Taiwan

Gefitinib as First-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients in Southern Taiwan

Gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, is effective in treating patients with non-small cell lung cancer (NSCLC) after unsuccessful chemotherapy. However, survival outcomes and predictors for its effectiveness in chemotherapy-naive NSCLC patients are still...

Full description

Bibliographic Details
Main Authors: Cheng-Ta Yang, Jen-Yu Hung, Chun-Liang Lai, Hsin-Chia Hung, Yung-Fa Lai, Meng-Chih Lin, Jiunn-Min Shieh, Ming-Shyang Huang
Format: Article
Language:English
Published: Wiley 2010-01-01
Series:Kaohsiung Journal of Medical Sciences
Subjects:
gefitinib
non-small cell lung cancer
target therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1607551X10700012

Internet

http://www.sciencedirect.com/science/article/pii/S1607551X10700012

Similar Items